MedTrace Logo

Acute and Chronic Effect of 250 mg Citicoline Consumption on Attention in Adults: A Randomized Trial

NCT05000190 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2022-11-14

No results posted yet for this study

Summary

The primary study objectives are to test whether among a sample of healthy adults consuming: (1) a single capsule containing 250 mg citicoline has an effect on attentional performance 1, 2 and 3 h post-dose compared to placebo (acute effect), and (2) capsule containing 250 mg citicoline per day for 28 consecutive days has an effect on attentional performance compared to placebo (chronic effect).

Conditions

  • Attention

Interventions

DIETARY_SUPPLEMENT

Active capsule

1 capsule daily for 28 days

OTHER

Placebo capsule

1 capsule daily for 28 days

Sponsors & Collaborators

  • PepsiCo Global R&D

    lead INDUSTRY

Principal Investigators

  • Patrick J O'Connor, PhD · University of Georgia, Athens

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-13
Primary Completion
2022-07-19
Completion
2022-07-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05000190 on ClinicalTrials.gov